Literature DB >> 19751191

Genetic variants of alpha1-antitrypsin.

Parveen Salahuddin1.   

Abstract

Alpha1-antitrypsin (alpha1-AT) is a 52 kDa sialoglycoprotein. The function of alpha1-antitrypsin is to protect the lower respiratory tract of lungs from proteolytic degradation by neutrophil elastase. Severe genetic deficiency of alpha1-AT is associated with early onset emphysema and liver diseases. alpha1-AT also exhibits anti-inflammatory activities independent of its protease inhibitor function. There are over 90 genetic variants of human alpha1-antitrypsin. These variants occur due to amino acid substitution / deletion which results in charge differences. Based on charge differences these variants have been identified by isoelectric focusing. The two most common deficiency variants are S and Z. The S variant migrates anodal to Z variant. The Z variant migrates most cathodal in isoelectric focusing, hence named Z. In Z variant, the beta-sheet A undergoes expansion, therefore it can easily accept the reactive site loop of a second alpha1-AT molecule and consequently form polymers of alpha1-AT. These polymers of alpha1-AT aggregate in the hepatocytes and show liver and lungs diseases. Contrary to this, the S variant of alpha1-AT is not associated with any significant clinical disease because the conformation of the inhibitor is not altered significantly. The Z related pathologies could be treated by liver transplantation, augmentation therapy, gene therapy, peptide therapy and chemical chaperone therapy. In addition to common deficiency variants, there are several rare deficiency variants of alpha1-AT like Siiyama, Mmalton, Mprocida, Mheerlen, Mmineral springs, Mnichinan, Pduarte, Wbethesda Zaugsberg, and Zbristol. In Siiyama, Mmalton, Mnichinan and Zaugsberg, the beta-sheet A is present in an open state therefore these variants readily undergo polymerization and consequently show aggregation in the hepatocytes. In Mprocida, Mheerlen, Mmineral springs, Pduarte and Wbethesda the conformation is altered significantly therefore these variants become conformationally less stable and thereby undergo intracellular proteolysis. These rare genetic variants show lungs and / or liver disease. There are several null variants of alpha1-AT that are not detected either at the stage of transcription or translation. The examples of some of the null variants are QOcardiff, QOhong kong, QOgranite falls, QObellingham, QOmattawa, QObolton, and QOludwigshafen. The molecular basis of deficiency of these variants also forms the theme of this review.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19751191     DOI: 10.2174/138920310790848368

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  21 in total

Review 1.  Alpha-1 Antitrypsin Deficiency-Mediated Liver Toxicity: Why Do Some Patients Do Poorly? What Do We Know So Far?

Authors:  Marion Bouchecareilh
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

Review 2.  Engineering the serpin α1 -antitrypsin: A diversity of goals and techniques.

Authors:  Benjamin M Scott; William P Sheffield
Journal:  Protein Sci       Date:  2019-12-09       Impact factor: 6.725

3.  Secretomic analysis identifies alpha-1 antitrypsin (A1AT) as a required protein in cancer cell migration, invasion, and pericellular fibronectin assembly for facilitating lung colonization of lung adenocarcinoma cells.

Authors:  Ying-Hua Chang; Shu-Hui Lee; I-Chuang Liao; Shin-Huei Huang; Hung-Chi Cheng; Pao-Chi Liao
Journal:  Mol Cell Proteomics       Date:  2012-08-15       Impact factor: 5.911

4.  Proteostasis: a new therapeutic paradigm for pulmonary disease.

Authors:  Marion Bouchecareilh; William E Balch
Journal:  Proc Am Thorac Soc       Date:  2011-05

Review 5.  Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy.

Authors:  Joanna Wozniak; Tomasz Wandtke; Piotr Kopinski; Joanna Chorostowska-Wynimko
Journal:  Hum Gene Ther       Date:  2015-09-29       Impact factor: 5.695

6.  Reticulophagy and ribophagy: regulated degradation of protein production factories.

Authors:  Eduardo Cebollero; Fulvio Reggiori; Claudine Kraft
Journal:  Int J Cell Biol       Date:  2012-02-28

7.  Deficient and Null Variants of SERPINA1 Are Proteotoxic in a Caenorhabditis elegans Model of α1-Antitrypsin Deficiency.

Authors:  Erin E Cummings; Linda P O'Reilly; Dale E King; Richard M Silverman; Mark T Miedel; Cliff J Luke; David H Perlmutter; Gary A Silverman; Stephen C Pak
Journal:  PLoS One       Date:  2015-10-29       Impact factor: 3.240

8.  Alternative transcripts of the SERPINA1 gene in alpha-1 antitrypsin deficiency.

Authors:  Nerea Matamala; Maria Teresa Martínez; Beatriz Lara; Laura Pérez; Irene Vázquez; Azucena Jimenez; Miguel Barquín; Ilaria Ferrarotti; Ignacio Blanco; Sabina Janciauskiene; Beatriz Martinez-Delgado
Journal:  J Transl Med       Date:  2015-07-04       Impact factor: 5.531

9.  Quantitation of circulating wild-type alpha-1-antitrypsin in heterozygous carriers of the S and Z deficiency alleles.

Authors:  L J Donato; R M Karras; J A Katzmann; D L Murray; M R Snyder
Journal:  Respir Res       Date:  2015-08-05

10.  Is an integrative laboratory algorithm more effective in detecting alpha-1-antitrypsin deficiency in patients with premature chronic obstructive pulmonary disease than AAT concentration based screening approach?

Authors:  Andjelo Beletic; Aleksandra Dudvarski-Ilic; Branislava Milenkovic; Ljudmila Nagorni-Obradovic; Mila Ljujic; Valentina Djordjevic; Dusko Mirkovic; Dragica Radojkovic; Nada Majkic-Singh
Journal:  Biochem Med (Zagreb)       Date:  2014-06-15       Impact factor: 2.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.